Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase I/II

Revive TherapeuticsCSE: RVV

2 Drug Candidates1 Trial

Canadian biotech developing psilocybin formulations for substance use disorders and neurological conditions. Lead programme is an oral psilocybin thin-film strip in a Phase I/II clinical trial for methamphetamine use disorder, with approximately 50% enrolment completed. Also conducting preclinical research on psilocybin for stroke recovery and inflammation.

Drug Pipeline

2

Psilocybin oral thin-film (methamphetamine use disorder)

Psilocybin
Phase I/II

Psilocybin delivered via oral thin-film strip. Phase I/II trial for methamphetamine use disorder; approximately 50% enrolled.

Psilocybin for stroke recovery

Psilocybin
Pre-clinical
Neurological Injury

Preclinical research on psilocybin to support neuroregeneration and functional recovery following stroke.

Quick Facts

Type
Public Biotech
Ticker
CSE: RVV
Lead Stage
Phase I/II
Website
Visit

Collaborated Trials

1
Active not recruitingI

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

Start Date
Compounds
Psilocybin